Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07426250 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Mar 1, 2026 to Mar 17, 2026 · Eligibility criteria expanded, about 6 words · Secondary endpoints: details revised at 2 of 9 entries · 1 more Show 4 more changesShow less
    • Start date changed from estimate of Mar 1, 2026 to Mar 17, 2026
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 2 of 9 entries
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This prospective observational study investigates the clinical utility of circulating tumor DNA (ctDNA) in patients with oligometastatic disease (OMD) undergoing definitive-intent local ablative treatment (LAT). The study aims to evaluate ctDNA as a prognostic and response biomarker before, during, and after LAT across cancer types and treatment modalities. Serial plasma samples and archival tumor tissue will be analyzed to assess ctDNA detection rates, elimination patterns, minimal residual disease, and association with recurrence, progression, and survival outcomes.
Trial Details
NCT Number NCT07426250
Lead Sponsor Aarhus University Hospital
Conditions Oligometastatic Cancer
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov